Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 189,529 shares of the medical research company’s stock after acquiring an additional 2,940 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Thermo Fisher Scientific were worth $35,859,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Covington Capital Management grew its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock worth $374,000 after purchasing an additional 20 shares during the last quarter. Investment Centers of America Inc. boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after acquiring an additional 21 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after acquiring an additional 23 shares in the last quarter. Azimuth Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after acquiring an additional 25 shares in the last quarter. Finally, Bienville Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after acquiring an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 85.32% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (TMO) opened at $191.00 on Tuesday. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $201.20. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The stock has a market cap of $76,180.00, a P/E ratio of 20.90, a price-to-earnings-growth ratio of 1.74 and a beta of 1.08.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter in the prior year, the firm earned $2.03 EPS. The company’s revenue was up 13.9% compared to the same quarter last year. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a $0.15 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. Thermo Fisher Scientific’s payout ratio is 10.19%.

Several research firms have recently issued reports on TMO. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Barclays PLC reiterated an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reissued an “overweight” rating and set a $220.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $205.71.

COPYRIGHT VIOLATION WARNING: “Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Grows Position in Thermo Fisher Scientific Inc (TMO)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/21/loring-wolcott-coolidge-fiduciary-advisors-llp-ma-grows-position-in-thermo-fisher-scientific-inc-tmo.html.

In other news, VP Seth H. Hoogasian sold 4,140 shares of the stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total transaction of $736,092.00. Following the transaction, the vice president now owns 25,518 shares in the company, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director C Martin Harris sold 360 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $65,149.20. Following the transaction, the director now owns 5,312 shares in the company, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,420 shares of company stock worth $11,308,477. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.